Fmr LLC Decreases Holdings in Agenus Inc. (NASDAQ:AGEN)

Modesto Morganelli
Novembre 14, 2017

The volume of 1.59 Million shares climbed up over an trading activity of 1.39 Million shares. The latest exchange of 0.62 Million shares is below its average trading activity of 345.57 Million shares. With an institutional ownership near 0%, it carries an earnings per share ratio of 1.03. We are encouraged by its efforts in developing Prophage vaccine for glioblastoma multiforme.Further, the company announced its strategic decision to spin off its cell therapy businesses as a separate unit. The stock was acquired at an average price of $3.55 per share, with a total value of $355,000.00.

Several research firms recently commented on AGEN. The Chairman & CEO added these shares by way of transaction on April 12, 2017. Zacks Investment Research upgraded shares of Agenus from a "hold" rating to a "buy" rating and set a $4.25 price target on the stock in a report on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock.

Multiple company employees have indulged in significant insider trading.

Currently, the stock carries a price to earnings ratio of 65.04, a price to book ratio of 14.2, and a price to sales ratio of 1.53. Agenus Inc. has a 1 year low of $3.20 and a 1 year high of $5.91.

Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, November 7th. The company had revenue of $3.40 million for the quarter, compared to analysts' expectations of $5.91 million. The firm's quarterly revenue was down 24.4% compared to the same quarter last year. equities analysts predict that Agenus will post -1.19 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. The legal version of this report can be accessed at https://stocknewstimes.com/2017/11/13/agenus-agen-earns-coverage-optimism-rating-of-0-15.html. In a transaction dated February 14, 2017, the shares were bought at an average price of $6, giving away a sum of $60,000,000.

In other Agenus news, CEO Garo H. Armen purchased 100,000 shares of Agenus stock in a transaction dated Monday, October 30th. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The company's institutional ownership is monitored at 47.6 percent. TIAA CREF Investment Management LLC now owns 204,576 shares of the biotechnology company's stock valued at $800,000 after purchasing an additional 1,283 shares during the last quarter. The stock witnessed -19.78% declines, -1.06% declines and 0.81% gains for the 1-month, 3-month and 6-month period, respectively. The Manufacturers Life Insurance Company increased its stake in Agenus by 6.7% during the 2nd quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company's stock valued at $3,682,000 after buying an additional 37,239 shares during the period. Finally, Teachers Advisors LLC raised its holdings in Agenus by 9.7% in the second quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company's stock valued at $160,000 after buying an additional 6,381 shares during the period. Institutional investors and hedge funds own 39.46% of the company's stock.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE